All In Biotech

Free tool

FAERS Monitor: Otezla

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 205437 or its brand name (Otezla, Apremilast). Reports on generic versions are filed under their own applications.

Reports

146,435

Serious

35,036

24% of reports

Hospitalization

11,809

Death reported

6,208

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea24,755
  • nausea22,292
  • psoriasis20,666
  • headache18,012
  • drug ineffective15,674
  • abdominal discomfort8,337
  • psoriatic arthropathy8,315
  • pain7,045
  • rash6,888
  • vomiting6,639
  • arthralgia6,531
  • fatigue6,327
  • depression5,640
  • off label use5,427
  • weight decreased5,094

Reports by year received

View as table
YearReports
20123
20134
20141,244
201512,439
201613,932
201718,313
201819,926
201922,848
202019,781
202110,551
20227,338
20235,928
20246,024
20254,946
20263,158

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,907,724 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
psoriatic arthropathySignal8,31536.735.9230,332
psoriasisSignal20,66626.826.4434,941
abdominal discomfortSignal8,3377.57.344,665
diarrhoeaSignal24,7555.75.694,890
headacheSignal18,0124.24.244,282
nauseaSignal22,2924.14.153,477
depressionSignal5,6403.63.510,569
weight decreasedSignal5,0942.72.65,210
rashSignal6,8882.32.25,029
arthralgiaSignal6,5312.32.24,691
vomitingSignal6,6392.02.03,563
drug ineffective15,6741.71.74,944
pain7,0451.71.61,858
fatigue6,3271.21.1158
off label use5,4270.90.977

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.